Holen Sie sich die Stockscreener-App
6.52
0.15%
0.010
Handel nachbörslich:
6.51
-0.010
-0.15%
Schlusskurs vom Vortag:
$6.51
Offen:
$6.4
24-Stunden-Volumen:
250.47K
Relative Volume:
0.80
Marktkapitalisierung:
$425.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.47M
KGV:
-6.4041
EPS:
-1.0181
Netto-Cashflow:
$-33.50M
1W Leistung:
+6.89%
1M Leistung:
-2.54%
6M Leistung:
-25.82%
1J Leistung:
+21.19%
1-Tages-Spanne:
$6.36
$6.645
1-Wochen-Bereich:
$5.79
$6.74
52-Wochen-Spanne:
$5.04
$9.32
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Firmenname
Eupraxia Pharmaceuticals Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare EPRX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
6.52 | 403.07M | 0 | -44.47M | -33.50M | -1.0181 |
VRTX
Vertex Pharmaceuticals Inc
|
478.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
760.66 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
844.50 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.46 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
323.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-23 | Eingeleitet | William Blair | Outperform |
| 2025-07-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-06-16 | Eingeleitet | Canaccord Genuity | Speculative Buy |
| 2025-02-21 | Eingeleitet | Craig Hallum | Buy |
| 2024-11-14 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals Inc (EPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Institutional Confidence - TradingKey
Why Eupraxia Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.810|Chg%:-0.490 - TradingKey
Eupraxia Pharmaceuticals, Inc. Revenue Breakdown – TSX:EPRX - TradingView
Eupraxia Pharmaceuticals Inc (EPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Cash Flow - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.955|Chg%:+0.145 - TradingKey
Eupraxia Pharmaceuticals Inc (EPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Eupraxia Pharmaceuticals Inc. (EPRX.TO) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
EPRX|Eupraxia Pharmaceuticals Inc|Price:5.910|Chg%:-0.390 - TradingKey
Eupraxia Pharmaceuticals (EPRX) Holds Steady Near Support Amid Low VolumeBullish Percent Index - dars.gov.et
Eupraxia Pharmaceuticals (EPRX) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Q3 2024 earnings summary - Quartr
Eupraxia Pharmaceuticals (EPRX) Bloom Burton & Co. Healthcare Investor Conference 2026 summary - Quartr
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
What's Going On With Eupraxia Pharmaceuticals Inc Stock Tuesday? - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is skyrocketing today - Wealth Awesome
Why Eupraxia Pharmaceuticals Inc stock is rising today - Wealth Awesome
Insider Stock Buying Reaches US$5.58m On Eupraxia Pharmaceuticals - simplywall.st
Why Eupraxia Pharmaceuticals Inc stock is plummeting today - Wealth Awesome
Eupraxia Pharmaceuticals (EPRX) reshapes leadership and expands Vancouver-Seattle hubs - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is sliding today - Wealth Awesome
Eupraxia names new executives, relocates operations By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals Overhauls Leadership and Operations Ahead of Key EoE Trial Milestone - TipRanks
Eupraxia names new executives, relocates operations - Investing.com
Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth - The Manila Times
Eupraxia Pharmaceuticals (NASDAQ: EPRX) adds senior leaders, prepares for Q4 2026 RESOLVE data - Stock Titan
Why Eupraxia Pharmaceuticals Inc stock is tanking today - Wealth Awesome
symbol__ Stock Quote Price and Forecast - CNN
Eupraxia Pharmaceuticals (EPRX) Gains 3.8% as Biotech Sector Shows Resilience – Key Levels to WatchLong Setup Ideas - dars.gov.et
Eupraxia Pharmaceuticals Adds Veteran Drug Developers to Board as Pipeline Advances - TipRanks
Eupraxia Pharmaceuticals (EPRX) adds three drug development and commercialization experts to board - Stock Titan
Eupraxia Pharmaceuticals appoints three directors to board - Investing.com
Eupraxia Pharmaceuticals appoints three directors to board By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization - Investing News Network
EPRX Technical Analysis & Stock Price Forecast - Intellectia AI
EPRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
EPRX Technical Analysis & ETF Price Forecast - Intellectia AI
A3EGRS Forecast — Price Target — Prediction for 2027 - TradingView
Eupraxia Pharmaceuticals (EPRX) Gains Momentum, Testing Key Resistance LevelsCall Flow Alert - dars.gov.et
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:EPRX) - TradingView
EPRX Forecast — Price Target — Prediction for 2027 - TradingView
Oppenheimer initiates Eupraxia stock with Outperform rating By Investing.com - Investing.com Nigeria
Eupraxia Pharmaceuticals, Inc. Actuals & Estimates (FWB:X43) - TradingView
Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17 - Moomoo
Finanzdaten der Eupraxia Pharmaceuticals Inc-Aktie (EPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):